drugset / Trial / NCT05996432
Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy
Phase 0
Recruiting
48 enrolled
Vanderbilt-Ingram Cancer Center
National Institutes of Health (NIH) · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.
Timeline
- Start
- 2023-05-17
- Primary completion
- 2026-11-30
- Completion
- 2029-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-fluoromisonidazole | Diagnostic / imaging agent | — | Intravenous |